GlassScriptPhysician profile
Arslan Shaukat
NPI 1114215134
$4,129.44
in general payments reported to CMS, 2019-2025
30 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,596 · 2020: $556 · 2021: $601 · 2022: $403 · 2023: $267 · 2024: $502 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Canon Medical Systems USA, INC. | $640.54 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $570.53 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $358.11 | 2019-2024 | |
| Amgen INC. | $332.47 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $299.11 | 2019-2021 | |
| Abiomed | $291.43 | 2019-2023 | Impella |
| E.R. Squibb & Sons, L.L.C. | $226.93 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $162.34 | 2021-2025 | Avvigo Guidance System, Watchman Access System, Watchman Flx |
| Lundbeck LLC | $128.51 | 2019-2020 | |
| Amarin Pharma, INC. | $127.86 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $117.89 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.40 | 2019-2025 | Jardiance |
| Abbott Laboratories | $92.06 | 2019 | |
| Pfizer INC. | $81.19 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $74.27 | 2021-2025 | Verquvo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $70.91 | 2019-2022 | |
| Philips North America LLC | $67.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.07 | 2021-2023 | |
| Shockwave Medical, INC | $54.57 | 2022 | |
| Esperion Therapeutics, INC. | $44.88 | 2020-2021 | |
| Cvrx, INC. | $40.95 | 2023 | Barostim Neo System |
| Novo Nordisk INC | $38.41 | 2023-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $34.86 | 2019 | |
| Vifor Pharma, INC. | $28.13 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.74 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $18.17 | 2023 | Arcalyst |
| Cardiva Medical, INC. | $17.59 | 2025 | Optowire |
| Emd Serono, INC. | $14.49 | 2020 | |
| Alnylam Pharmaceuticals INC. | $12.07 | 2022 | |
| Tactile Systems Technology INC | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arslan Shaukat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.